Thu, Sep 24, 1:30 PM - 2:45 PM
TBD
Global Impact of COVID-19 on the Design and Analysis of Clinical Trials and the Path Forward
Panel Discussion (302306)
*
Sylva Collins, FDA/CDER/OTS
*
Mark Steven Levenson, FDA/CDER
*
Daniel Li, BMS
*
Dan Meyer, Pfizer
*
Frank Pétavy, European Medicines Agency
